AIMD logo

AINOS INC

AIMDNASDAQ
🏆 #5013 by market capUS Equity
$1.25▼ $0.08 (−6.02%)
After hours · at close
🔔
Track AIMD
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 6.0%
7d▼ 13.8%
14d▼ 10.7%
30d▼ 10.1%
ytd▼ 23.8%
1y▼ 63.9%
🏦Market Cap
$9M
Small Cap
📈Revenue Growth (YoY)
+498.9%
High Growth
📊Gross Margin
-34987.5%
Thin
💵FCF Margin
-33046.9%
Thin
⚖️P/S Ratio
720.2x
Expensive
Otter Score
72
Fair

Trading Snapshot

Day Range
$1.23 – $1.26
52-Week Range
$1.25 – $4.44
Volume
$2.52B
Avg Volume
$2.74B
Shares Outstanding
7.4M
Next Earnings
Oct 21, 2026

Fundamentals Snapshot

Annual Revenue
$124,157
Last Q Revenue
$152
P/E Ratio
-0.5
P/S Ratio
720.2x
EPS (TTM)
$-1.96
Dividend Yield
0.00%
Dilution (1yr)
−36.5%

Why Investors Own AIMD

  • ✓High-growth profile — revenue up +43.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 62% gross margin and 16% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AIMD logo

AINOS INC

AIMD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$124K▲ +499.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-3767.2%▲ +2350.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$14M▲ +1.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▼ −20.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
6.0M▼ −36.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$11M▼ −$2M YoY
StockOtter · stockotter.space

About AINOS INC

Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$1.33
▲ +6.5% Upside
High Target$1.49
Low Target$0.99
Based on 39 analysts

Latest News & Updates

🚀
Reuters·2h ago

AINOS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift AIMD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

AINOS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.